There was a twofold increase in risk of phlebitis, thrombophlebitis, and thromboembolism for survivors (HR, 2.07, 99% CI, 1.57-2.72), and risk remained elevated in the 5- to 10-year time frame (HR, 1.53; 99% CI, 1.08-2.17), data show.
Similar increases in risk were reported for other cardiovascular diseases at 1-5 years, and in some cases also at 5-10 years. Cerebrovascular disease was the only major category where no increased risk was found among endometrial cancer survivors, the investigators said.
Type of cancer treatment also may have influenced risk. Among patients who had endometrial cancer, radiation therapy and chemotherapy both increased risk for cardiovascular disorders versus surgery. Advanced age and obesity may have increased risk, the investigators added.
“Studies that examine risk for long-term cardiovascular outcomes among endometrial cancer survivors are becoming increasingly more critical because of the high overall survival rate among individuals diagnosed with endometrial cancer, the large number of endometrial cancer survivors, the projected increase in the number of endometrial cancer diagnoses, the introduction of more complex therapies, and the high mortality due to cardiovascular disease among endometrial cancer survivors,” the authors wrote.
The National Cancer Institute and other organizations supported the study. The authors had no conflicts of interest to disclose.
SOURCE: Soisson S, et al. J Natl Cancer Inst. 2018 May 8. doi: 10.1093/jnci/djy070.